Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase …
EL Simpson, JP Lacour, L Spelman… - British Journal of …, 2020 - academic.oup.com
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …
Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
EL Simpson, S Forman, JI Silverberg, M Zirwas… - Journal of the American …, 2021 - Elsevier
Background Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being
studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the …
studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the …
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
E Guttman-Yassky, JI Silverberg, O Nemoto… - Journal of the American …, 2019 - Elsevier
Background Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2,
modulates proinflammatory cytokine signaling. Objectives The efficacy and safety of …
modulates proinflammatory cytokine signaling. Objectives The efficacy and safety of …
Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials
B King, C Maari, E Lain, JI Silverberg, M Issa… - American Journal of …, 2021 - Springer
Abstract Background Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is
indicated in the European Union and Japan for the treatment of moderate-to-severe atopic …
indicated in the European Union and Japan for the treatment of moderate-to-severe atopic …
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes …
K Reich, AM DeLozier, FP Nunes… - Journal of …, 2022 - Taylor & Francis
Background Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic
dermatitis (AD) that negatively influence a patient's quality of life (QoL). Objective To …
dermatitis (AD) that negatively influence a patient's quality of life (QoL). Objective To …
Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial
K Reich, K Kabashima, K Peris, JI Silverberg… - JAMA …, 2020 - jamanetwork.com
Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate …
A Torrelo, B Rewerska, M Galimberti… - British Journal of …, 2023 - academic.oup.com
Background Baricitinib, an oral selective Janus kinase (JAK) 1/JAK2 inhibitor, is approved in
many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates …
many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates …
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance …
T Bieber, K Reich, C Paul, Y Tsunemi… - British Journal of …, 2022 - academic.oup.com
Background Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was
shown to improve the signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) …
shown to improve the signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) …
Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 …
JI Silverberg, EL Simpson, A Wollenberg… - JAMA …, 2021 - jamanetwork.com
Importance Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs
and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy …
and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy …
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical …
T Bieber, N Katoh, EL Simpson… - Journal of …, 2023 - Taylor & Francis
Abstract Background Baricitinib, a selective Janus kinase (JAK) 1/JAK2 inhibitor, is
approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We …
approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We …
相关搜索
- monotherapy phase baricitinib in patients
- monotherapy phase topical corticosteroids
- monotherapy phase atopic dermatitis
- atopic dermatitis safety analysis
- baricitinib in patients topical corticosteroids
- monotherapy phase inadequate response
- atopic dermatitis topical corticosteroids
- atopic dermatitis inadequate response
- inadequate response topical corticosteroids
- symptoms in patients inadequate response
- efficacy and safety topical corticosteroids
- monotherapy phase breeze ad5
- baricitinib in patients breeze ad5
- atopic dermatitis breeze ad5
- atopic dermatitis baricitinib in patients
- safety of baricitinib topical corticosteroids